Table 1.

Antiproliferative activity of synthesized bromolactones 5–7 and iodolactones 9,10 ¹ against the selected cancer cell lines. ²

Entry	Compound	IC50 [μg/mL] 3
		D17	CLBL-1	CLB70	GL-1	Jurkat
1	(4R,5R,6S)-5	>50	45.86 ± 3.50	31.30 ± 4.20	31.10 ± 3.89	32.51 ± 2.1
2	(4S,5S,6R)-5	>50	33.35 ± 0.40	21.39 ± 5.40	15.65 ± 1.20	30.80 ± 4.90
3	(4R,5R,6S)-6	>50	33.27 ± 2.40	19.61 ± 3.70	14.74 ± 2.87	22.47 ± 2.30
4	(4S,5S,6R)-6	>50	30.98 ± 1.90	13.21 ± 2.30	8.51 ± 0.81	14.48 ± 5.20
5	(4R,5S,6R)-7	>50	18.09 ± 3.33	20.08 ± 0.32	14.92 ± 0.48	16.73 ± 3.40
6	(4S,5R,6S)-7	34.31 ± 1.88	14.33 ± 2.53	15.80 ± 0.15	6.97 ± 0.45	9.80 ± 2.10
7	(4R,5R,6S)-9	19.39 ± 2.60	8.07 ± 1.21	n.i. 4	25.65 ± 4.3	29.40 ± 1.66
8	(4S,5S,6R)-9	26.57 ± 3.54	8.01 ± 0.96	n.i.	20.48 ± 3.95	33.84 ± 6.85
9	(4R,5S,6R)-10	14.81 ± 3.39	7.10 ± 0.65	n.i.	14.24 ± 6.06	14.30 ± 3.72
10	(4S,5R,6S)-10	16.99 ± 4.88	4.76 ± 0.52	n.i.	16.30 ± 4.69	16.16 ± 4.73
11	carboplatin	13.10± 4.30	n.i.	n.i.	7.06± 1.15	21.37± 4.00

¹ Data for iodolactones (entries 7–10) reported in previous paper [24]; ² Results obtained from more than three independent experiments (four wells each) and expressed as the mean value ± SD (standard deviation); ³ IC₅₀: anticancer drug concentration inhibiting cell viability by 50%; ⁴ n.i.: not investigated.